Business Context and Reporting Period
This Form 8-K, dated April 13, 2011, reports on RXi Pharmaceuticals Corporation (now SELLAS Life Sciences Group, Inc.). The filing details the completion of the acquisition of Apthera, Inc. and the appointment of two new executive officers effective April 13, 2011.
Key Financial Metrics and Transaction Terms
- Acquisition Consideration: RXi issued approximately 4.8 million shares of common stock to Apthera stockholders.
- Contingent Consideration: Up to $32 million in additional payments may be required based on development and commercial milestones for Apthera's NeuVax product candidate. Payment may be made in cash or stock (subject to shareholder approval).
- Escrow Arrangement: 10% of the aggregate stock consideration was deposited into escrow to cover potential indemnifiable losses.
- Executive Compensation:
- Mark W. Schwartz (EVP & COO): Initial annual base salary of $225,000; granted options for 40,000 shares at $1.275/share.
- Robert E. Kennedy (VP & CFO): Initial annual base salary of $175,000; granted options for 30,000 shares at $1.275/share.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company or the acquired entity. Financial statements and pro forma information are scheduled to be filed within 71 days.
Material Changes
- Asset Acquisition: Apthera, Inc. is now a wholly-owned subsidiary of RXi Pharmaceuticals Corporation.
- Leadership Changes:
- Mark W. Schwartz appointed Executive Vice President and Chief Operating Officer.
- Robert E. Kennedy appointed Vice President and Chief Financial Officer.
- Related Party Transaction: Sanford Hillsberg, Chairman of RXi's Board, owned approximately 2.4% of Apthera prior to the merger and received consideration on the same terms as other stockholders. He recused himself from the vote.
Outlook, Risks, and Contingencies
- Contingent Liability: The company faces a potential future cash or equity outflow of up to $32 million dependent on the success of the NeuVax product candidate.
- Employment Contingencies: Executive employment agreements include salary increases tied to future financing transactions (net proceeds of $5 million or $10 million). Termination without cause triggers continued salary payments and option vesting.
- Regulatory Requirement: Issuance of stock for contingent consideration requires shareholder approval under NASDAQ Listing Rules.
Investor Verification Checklist
- Verify the specific development and commercial milestones required to trigger the $32 million contingent payment.
- Confirm the status of the shareholder vote required to issue stock for contingent consideration.
- Review the upcoming 10-Q filing (due within 71 days) for the financial statements of Apthera and pro forma financial information.
- Monitor future financing activities to determine if executive salary triggers ($5M/$10M net proceeds) are met.